Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against respiratory infections, and clinical trials of probiotics show promise in this regard in healthy adults and children. However, comparable studies are lacking in overweight/obese people, who have increased risks in particular of viral upper respiratory tract infections (URTI). This Addendum further analyses our recent placebo-controlled trial of probiotics in overweight/obese people (focused initially on weight loss) to investigate the impact of probiotics upon the occurrence of URTI symptoms. As well as undergoing loss of weight and improvement in certain metabolic parameters, study participants taking probiotics experienced a 27% reduction in URTI symptoms versus control, with those ≥45 years or BMI ≥30 kg/m2 experiencing greater reductions. This symptom reduction is apparent within 2 weeks of probiotic use. Gut microbiome diversity remained stable throughout the study in probiotic-treated participants. Our data provide support for further trials to assess the potential role of probiotics in preventing viral URTI (and possibly also COVID-19), particularly in overweight/obese people.
Neurodegeneration has been linked to changes in the gut microbiota and this study compares the neuroprotective capability of two bacterial consortia, known as Lab4 and Lab4b, using the established SH-SY5Y neuronal cell model. Firstly, varying total antioxidant capacities (TAC) were identified in the intact cells from each consortia and their secreted metabolites, referred to as conditioned media (CM). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and Crystal Violet (CV) assays of cell viability revealed that Lab4 CM and Lab4b CM could induce similar levels of proliferation in SH-SY5Y cells and, despite divergent TAC, possessed a comparable ability to protect undifferentiated and retinoic acid-differentiated cells from the cytotoxic actions of rotenone and undifferentiated cells from the cytotoxic actions of 1-methyl-4-phenylpyridinium iodide (MPP+). Lab4 CM and Lab4b CM also had the ability to attenuate rotenone-induced apoptosis and necrosis with Lab4b inducing the greater effect. Both consortia showed an analogous ability to attenuate intracellular reactive oxygen species accumulation in SH-SY5Y cells although the differential upregulation of genes encoding glutathione reductase and superoxide dismutase by Lab4 CM and Lab4b CM, respectively, implicates the involvement of consortia-specific antioxidative mechanisms of action. This study implicates Lab4 and Lab4b as potential neuroprotective agents and justifies their inclusion in further in vivo studies.
The effects of probiotics on the gut microbiota and microbial metabolites in healthy individuals are not well understood. Faecal and serum samples were collected at the start and end of a 3-month, double-blind, placebo-controlled, randomised study with three different probiotic formulations in free-living, healthy adults. The composition of the faecal microbiota and levels of faecal and/or serum short-chain fatty acids (SCFA) and bile acids (BA) were measured and the probiotic formulations were found to impart differing effects including shifts in the composition and structure of the faecal microbiota, enhanced levels of circulating short chain fatty acids such as butyrate and propionate, and elevated levels of sulphated bile acids in faeces. This was in contrast to the outcomes for the placebo population where very little change occurred over the study. These findings demonstrate that probiotic supplementation elicits formulation specific effects and that there are potential benefits for healthy individuals.
The gut microbiota is a vast community of microorganisms that forms part of a complex communication network linking the gastrointestinal tract with the immune system and central nervous system.1 Th...
This double-blind, randomised, placebo-controlled pilot study investigated the effects of a six-strain probiotic formulation containing Lactobacillus crispatus CUL40 and L. gasseri CUL09 on vaginal microbiota composition and well-being in 40 women with recurrent vaginal discomfort. Participants received either the probiotic (20 billion colony-forming units/day) or placebo for 20 days. Vaginal samples collected at baseline, midpoint and endpoint were analysed using shotgun metagenomic sequencing, microbial culture and species- and strain-specific quantitative polymerase chain reaction. Vaginal symptoms and broader well-being were recorded daily. At endpoint, vaginal detection of CUL40 and CUL09 was significantly higher in the probiotic group, with neither strain detected in the placebo group. Viable L. crispatus CUL40 was recovered from vaginal cultures, whereas viable CUL09 was not recovered. L. gasseri relative abundance was significantly higher in the probiotic group at midpoint and endpoint, while Gardnerella counts were significantly lower at endpoint. Probiotic supplementation significantly influenced beta diversity over time between groups, although community state types remained broadly stable. During the second half of the intervention, rates of vaginal itchiness, burning sensation and anxiousness were significantly lower in the probiotic group. Bloating was also less frequent throughout the intervention. These findings demonstrate increased vaginal detection of orally administered probiotic strains, including recovery of viable CUL40, alongside changes in vaginal microbiota composition and reduced vaginal discomfort. Larger studies are warranted to confirm these exploratory findings and establish longer-term effects. This trial was registered at ClinicalTrials.gov ( NCT07364383 ). Importance: Evidence that probiotic bacteria taken orally can subsequently be detected alive in the vagina remains limited. In this pilot trial, we combined genetic testing with bacterial culture to investigate vaginal detection of Lactobacillus crispatus CUL40 and Lactobacillus gasseri CUL09 following oral supplementation. Both strains were detected, and viable CUL40 bacteria were recovered. These findings were accompanied by changes in vaginal bacterial communities and reduced reporting of some symptoms. The study provides evidence to guide further research into oral probiotics and vaginal health.